GENFIT Announces U.S. Medicare Coverage and Future Reimbursement for NASHnext®, a Non-Invasive Diagnostic Technology to Identify Patients with At-Risk MASH

GENFIT secured U.S. Medicare coverage for its NASHnext® non-invasive blood test (available via Labcorp), with reimbursement set at ~US$252 per test under the Clinical Laboratory Fee Schedule effective August 10, 2026. The update supports large-scale adoption and creates a second revenue stream for GENFIT through its licensing deal with Labcorp. The article also cites a large target population (e.g., ~170M diagnosed with metabolic disease; ~90M with elevated liver enzymes/steatosis), positioning NASHnext® at a key inflection point as MASH therapies expand.

Analysis

This is more valuable as a funnel-expansion event than as a near-term revenue driver for the test owner. The economics likely accrue first to the distributor with the installed salesforce and lab workflow, while GENFIT’s upside is the optionality on a second recurring stream; that usually deserves a higher multiple only after investors see volume, not just coverage. The market is probably underestimating how a reimbursed blood test can lower patient-acquisition costs for the entire MASH drug stack, which is the real second-order winner over the next 6-18 months.

The first 30-90 days are about whether private payers follow Medicare and whether the test gets embedded into endocrine/primary-care order sets. If utilization stays specialist-only, the revenue opportunity remains modest; if it gets pulled into routine metabolic workups, the addressable pool could expand sharply. For Labcorp, the incremental margin may be better than the headline price suggests because this is a high-frequency, low-capex menu item that can increase stickiness in metabolic testing.

The contrarian risk is that reimbursement can cap adoption if ordering friction remains high or if payers impose narrow criteria. The consensus is likely treating this as a clean positive, but the real falsifier is weak test volume by the fall guidance event or no private-payer follow-through by year-end 2026. In that case, the story reverts to a press-release multiple rather than a durable earnings stream.

Key Decisions for Investors

• Long GNFTY into the August 10 reimbursement effective date and fall guidance window; size small due liquidity, with the thesis invalidated if management frames royalties as immaterial or if initial volume data disappoints.
• Add MDGL on pullbacks as a 6-18 month beneficiary of a larger diagnosed MASH pool; use the first 1-3 months to confirm payer adoption, and reduce if reimbursement fails to broaden beyond Medicare.
• No direct trade in LH yet; treat as a watch item until Labcorp reports actual NASHnext volume or margin contribution, since the current risk/reward looks more optically positive than earnings-relevant.